Companies /Healthcare

Entrada Therapeutics Inc

NASDAQ: TRDA Biotechnology
$5.00
▼ $0.09 (−1.77%) today
Markets closed · 5:42pm ET

TRDA at a Glance

Valuation
Market cap
$199.3M
Profitability
Revenue (TTM)
$4.0M
EPS (TTM)
$-3.84
Price
52-week range
$4 – $16
Street target
$18.75

Headquartered in Boston, MA Fiscal year ends December NASDAQ: TRDA entradatx.com

About Entrada Therapeutics

Entrada Therapeutics is a clinical-stage biopharmaceutical company developing a new class of genetic medicines. Its proprietary Endosomal Escape Vehicle (EEV) approach is designed to engage intracellular targets long considered inaccessible.

Its lead oligonucleotide programs target Duchenne muscular dystrophy patients amenable to exon 44, 45, 50 and 51 skipping:
- ENTR-601-44 is in the Phase 1/2 ELEVATE-44-201 study, with a planned U.S. adult study, ELEVATE-44-102.
- ENTR-601-45 is in the Phase 1/2 ELEVATE-45-201 study and holds FDA orphan drug designation.
- ENTR-601-50 and ENTR-601-51 are earlier-stage programs.

Clinical studies run in the U.K., EU and U.S., with a long-term extension platform study (ENTR-DMD-202) for participants.

Entrada also partners with Vertex on VX-670, a clinical-stage candidate for myotonic dystrophy type 1. This collaboration is currently the company's only source of revenue.

Beyond neuromuscular disease, the company is expanding preclinical work into inherited retinal and metabolic diseases. This includes ENTR-801 for Usher syndrome type 2A and a planned second ocular clinical candidate. Updated

TRDA Coverage

Frequently Asked Questions

What does Entrada Therapeutics do?

Entrada Therapeutics is a clinical-stage biopharmaceutical company developing a new class of genetic medicines. Its proprietary Endosomal Escape Vehicle (EEV) approach is designed to engage intracellular targets long considered inaccessible.

What is the TRDA stock price target?

The Wall Street consensus 12-month price target for TRDA is $18.75.